Full Press Release Details
Tiziana Life Sciences to participate in a Fireside
At the B. Riley Securities 2022 Oncology Conference
NEW YORK - 26 January 2022 - Tiziana
Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company
developing breakthrough therapies for KRAS+ Non-Small Cell Lung Cancer (NSCLC) and transformational drug delivery technologies to enable
alternative routes of immunotherapy, today announced its Chief Executive Officer and Chief Scientific Officer, Kunwar Shailubhai, Ph.D.,
will participate in a virtual fireside chat at the B.Riley Securities 2022 Oncology Conference on Thursday, 27 January 2022 at 4:00 p.m.
EDT (U.S. and Canada) to provide Company updates.
| Date: | Thursday, 27 January 2022 |
| Time: | 4:00 p.m. Eastern Daylight Savings Time (US and Canada) |
| Webcast: | Click this link to access: https://www.webcaster4.com/Webcast/Page/2828/44467 |
| Location: | Track 1 |
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical
company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.
Tiziana's innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy
as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's two lead candidates, intranasal foralumab,
the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical
response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several
applications pending and is expected to allow for broad pipeline applications.
For further information please contact:
Hana Malik, Business Development and Investor Relations Manager
+44 (0) 207 495 2379
email: info@tizianalifesciences.com